T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany
Ahmadi P, Alsdorf W, Leypoldt L, Kosch R, Schaefers C, Gagelmann N, Ayuk F, Kron F, Weisel K
BONE MARROW TRANSPL. 2025;60(4):538-540.

BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords L, Schaefers C, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel K
HAEMATOLOGICA. 2024;109(9):3071-3077.

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample
Kamili A, Ahmadi P, Leypoldt L, Marquard F, Schaefers C, Kosch R, Peters F, Kusche H, Zamrik T, Hanoun C, Seib M, Shumilov E, Leitner T, Khandanpour C, Bokemeyer C, Weisel K, Ghandili S
HAEMATOLOGICA. 2024;109(11):3795-3799.

IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
Krzikalla D, Laschtowitz A, Leypoldt L, Gottwick C, Averhoff P, Weidemann S, Lohse A, Huber S, Schramm C, Schwinge D, Herkel J, Carambia A
CELL MOL GASTROENTER. 2024;17(1):79-91.

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt L, Tichy D, Besemer B, Hänel M, Raab M, Mann C, Munder M, Reinhardt H, Nogai A, Görner M, Ko Y, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel K
J CLIN ONCOL. 2024;42(1):26-37.

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma
Leypoldt L, Tichy D, Besemer B, Hänel M, Raab M, Mann C, Munder M, Reinhardt H, Nogai A, Görner M, Ko Y, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel K
FUTURE ONCOL. 2024;20(39):3193-3207.

Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma—A Pilot Study
Oelschläger L, Künstner A, Frey F, Leitner T, Leypoldt L, Reimer N, Gebauer N, Bastian L, Weisel K, Sailer V, Röcken C, Klapper W, Konukiewitz B, Penas E, Forster M, Schub N, Ahmed H, Kirfel J, Bubnoff N, Busch H, Khandanpour C
INT J MOL SCI. 2024;25(24):.

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Rees M, D'Agostino M, Leypoldt L, Kumar S, Weisel K, Gay F
ASCO Educational Book. 2024;44(3):e433520.

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
Ghandili S, Alihodzic D, Wiessner C, Bokemeyer C, Weisel K, Leypoldt L
ANN HEMATOL. 2023;102(1):117-124.

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Leypoldt L, Gavriatopoulou M, Besemer B, Salwender H, Raab M, Nogai A, Khandanpour C, Runde V, Jauch A, Zago M, Martus P, Goldschmidt H, Bokemeyer C, Dimopoulos M, Weisel K
CANCERS. 2023;15(18):.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
Leypoldt L, Besemer B, Asemissen A, Hänel M, Blau I, Görner M, Ko Y, Reinhardt H, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel K
LEUKEMIA. 2022;36(3):885-888.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck F, Weimer P, Schulze zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W
FRONT MED-LAUSANNE. 2021;8:763773.

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
Ghandili S, Schönlein M, Lütgehetmann M, Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
CANCERS. 2021;13(15):.

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm T, Wiesch J, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
J CLIN MED. 2021;10(23):.

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili S, Weisel K, Bokemeyer C, Leypoldt L
ONCOL RES TREAT. 2021;44(12):690-699.

Untersuchung von Mechanismen der hepatischen Immuntoleranz im Tiermodell der Experimentellen Autoimmunen Enzephalomyelitis
Leypoldt L
2021.

56/m mit Rückenschmerzen und Konzentrationsstörungen
Leypoldt L, Weisel K
ONKOLOGE. 2021;2021(27 supplement issue 1):27-32.

Letzte Aktualisierung aus dem FIS: 09.05.2025 - 06:56 Uhr